{"id":175843,"date":"2026-08-17T16:03:52","date_gmt":"2026-08-17T10:33:52","guid":{"rendered":"https:\/\/signalz.pro\/?post_type=article&p=175843"},"modified":"2026-08-17T16:03:52","modified_gmt":"2026-08-17T10:33:52","slug":"senores-pharma-fy25-annual-report-what-investors-should-know-%f0%9f%94%8d","status":"publish","type":"article","link":"https:\/\/signalz.pro\/article\/senores-pharma-fy25-annual-report-what-investors-should-know-%f0%9f%94%8d\/","title":{"rendered":"SENores PHARMA | FY25 ANNUAL REPORT \u2014 WHAT INVESTORS SHOULD KNOW \ud83d\udd0d"},"content":{"rendered":"
\n
\n
\n
\n

SENores PHARMA | FY25 ANNUAL REPORT \u2014 WHAT INVESTORS SHOULD KNOW \ud83d\udd0d<\/h3>\n

Senores Pharmaceuticals delivered a breakout year<\/strong> in its first year as a listed company.<\/p>\n

\ud83d\udcc8 Revenue +92% YoY<\/strong>
\ud83d\udd25 EBITDA +148% YoY<\/strong>
\ud83d\udcca EBITDA Margin: 27%<\/strong> | +640 bps
\ud83c\uddfa\ud83c\uddf8 ~70% revenue from the US<\/strong><\/p>\n

The strategy is clear: focus on specialty, niche & complex generics<\/strong> where competition is relatively lower.<\/p>\n

\ud83d\ude80 Growth Engines<\/h3>\n

\u2022 CDMO\/CMO:<\/strong> 22 commercial products + 69 in pipeline
\u2022 API backward integration:<\/strong> Gujarat capacity expanded 25 \u2192 169 MTPA<\/strong>
\u2022 Injectables:<\/strong> \u20b943.55 Cr IPO allocation
\u2022 Acquisitions of Havix & Ratnatris<\/strong> strengthening the global platform
\u2022 Emerging markets targeted for higher-value niche molecules<\/p>\n

\ud83d\udcb0 Financial & Governance Check<\/h3>\n

Consolidated contingent liabilities: \u20b920.93 Cr<\/strong>, largely disputed income-tax demands.<\/p>\n

Management remuneration stood at \u20b98.49 Cr<\/strong>, while MD remuneration rose 236.7% YoY<\/strong> vs 78.3% PAT growth<\/strong> \u2014 worth monitoring.<\/p>\n

Auditor gave a clean\/unmodified opinion<\/strong>, with revenue recognition identified as a key audit area.<\/p>\n

\u26a0\ufe0f KEY RISK<\/h3>\n

The biggest opportunity is also a major risk:<\/p>\n

~70% revenue comes from the US.<\/strong><\/p>\n

That provides scale and access to an attractive market, but increases exposure to US regulatory changes, pricing pressure and protectionist policies<\/strong>.<\/p>\n

\ud83e\udde0 NEHA GUPTA | SEBI RA<\/h3>\n

Senores is transitioning from a high-growth pharma manufacturer \u2192 vertically integrated platform<\/strong> through APIs, injectables, CDMO and complex generics.<\/p>\n

The numbers show strong execution.<\/p>\n

Now the real test is:<\/p>\n

Can capacity expansion + pipeline + acquisitions translate into sustainable cash flows and returns?<\/strong><\/p>\n

That\u2019s the key metric I\u2019ll be watching.<\/p>\n

\u2014 Neha Gupta<\/strong>
SEBI Registered Research Analyst<\/strong><\/p>\n

For educational purposes only. Not investment advice.<\/em><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n

<\/div>\n
<\/div>\n","protected":false},"template":"","article-category":[],"article-tags":[],"class_list":["post-175843","article","type-article","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/signalz.pro\/api\/wp\/v2\/article\/175843","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/signalz.pro\/api\/wp\/v2\/article"}],"about":[{"href":"https:\/\/signalz.pro\/api\/wp\/v2\/types\/article"}],"wp:attachment":[{"href":"https:\/\/signalz.pro\/api\/wp\/v2\/media?parent=175843"}],"wp:term":[{"taxonomy":"article-category","embeddable":true,"href":"https:\/\/signalz.pro\/api\/wp\/v2\/article-category?post=175843"},{"taxonomy":"article-tags","embeddable":true,"href":"https:\/\/signalz.pro\/api\/wp\/v2\/article-tags?post=175843"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}